NasdaqGS:QUREBiotechs
A Look At uniQure (QURE) Valuation After FDA Feedback On AMT-130 Delays BLA Timeline
The FDA has informed uniQure (QURE) that existing Phase I/II data for its Huntington’s disease gene therapy AMT-130 is not sufficient for a Biologics License Application, and the company now plans to hold a Type A meeting in Q1 2026.
See our latest analysis for uniQure.
At a share price of $21.995, uniQure has seen a 1 day share price return of 1.59% decline and a 7 day share price return of 4.99% decline, while its 90 day share price return of 62.08% decline contrasts with a 1 year total...